<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975893</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1647-P202-EXT</org_study_id>
    <nct_id>NCT04975893</nct_id>
  </id_info>
  <brief_title>A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine</brief_title>
  <official_title>A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine in Participants Who Completed Study mRNA-1647-P202</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the longer-term immune persistence of mRNA-1647&#xD;
      vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study&#xD;
      mRNA-1647-P202 (NCT04232280).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to explore the long-term potential differences in immunogenicity and key&#xD;
      safety parameters following mRNA-1647 administration in CMV-seronegative and CMV-seropositive&#xD;
      participants. Study mRNA-1647-P202 participants who are CMV-seronegative and who did not&#xD;
      seroconvert due to primary CMV infection during the study will be enrolled. Study&#xD;
      mRNA-1647-P202 participants who were CMV-seropositive at baseline, randomized to receive&#xD;
      mRNA-1647 injection, and completed their final study visit will also be enrolled.&#xD;
&#xD;
      No study treatment will be administered during this extension study. Eligible participants&#xD;
      enrolling in the extension study who completed Study mRNA-1647-P202 may have received&#xD;
      mRNA-1647 (either low dose, medium dose, or high dose) or placebo in CMV-seronegative&#xD;
      participants and mRNA-1647 (either low dose, medium dose, or high dose) in CMV-seropositive&#xD;
      participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antigen-Specific Neutralizing Antibody (nAb) and Binding Antibody (bAb)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) Leading to Study Discontinuation</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Died</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">446</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>CMV-seropositive and CMV-seronegative Participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CMV-seropositive and CMV-seronegative participants who completed Study mRNA-1647-P202 will be followed every 6 months for 3 years in this study after the final visit in Study mRNA-1647-P202.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1647</intervention_name>
    <description>No investigational product will be administered in this extension study.</description>
    <arm_group_label>CMV-seropositive and CMV-seronegative Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants who were CMV-seronegative at the Study mRNA-1647-P202&#xD;
             Screening visit, completed the final Study mRNA-1647-P202 visit, and remained&#xD;
             CMV-seronegative at Screening for Study mRNA-1647-P202-EXT.&#xD;
&#xD;
          -  Male and female participants who were CMV-seropositive at the Study mRNA-1647-P202&#xD;
             Screening visit, were randomized to receive mRNA-1647 injection (and not placebo), and&#xD;
             completed the final visit in Study mRNA-1647-P202.&#xD;
&#xD;
          -  Understands and agrees to comply with the trial procedures and provides written&#xD;
             informed consent.&#xD;
&#xD;
          -  According to the assessment of the Investigator, is in good general health and is&#xD;
             capable of complying with trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any CMV vaccine other than mRNA-1647.&#xD;
&#xD;
          -  Diagnosis or condition that, in the judgment of the Investigator, may affect&#xD;
             participant safety, assessment of safety endpoints, assessment of immune response, or&#xD;
             adherence to trial procedures, including any medical, psychiatric, or occupational&#xD;
             condition that, in the opinion of the Investigator, might pose additional risk due to&#xD;
             participation in the study or could interfere with the interpretation of study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispeciality Research, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research (Victoria)</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderna</keyword>
  <keyword>mRNA-1647</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>Cytomegalovirus Vaccine</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Cytomegalovirus Congenital</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Infection Viral</keyword>
  <keyword>DNA Virus Infections</keyword>
  <keyword>Messenger RNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

